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Abstract Interferon regulatory factor 8 (Irf8) is a
transcription factor that negatively regulates osteo-
clast differentiation and Irf8 global knockout (Irf8-/-)
mice have been shown to have reduced bone volume
resulting from increased osteoclast numbers. How-
ever, detailed analysis of the functions of Irf8 in
osteoclast precursors with a monocyte/macrophage
linage is difficult, because the population and proper-
ties of hematopoietic cells in Irf8-/-mice are severely
altered. Therefore, to clearly elucidate the functions of
Irf8 during osteoclastogenesis, we established mye-
loid cell-specific Irf8 conditional knockout (Irf8fl/fl;
Lyz2cre/?) mice. We found that trabecular bone
volume in the Irf8fl/fl;Lyz2cre/? mice was not signifi-
cantly affected, while exposure to M-CSF and
RANKL significantly increased TRAP activity
in vitro in osteoclasts that underwent osteoclastogen-
esis from bone marrow-derived macrophages (BMMs)
induced from bone marrow cells (BMCs) of those
mice by addition of M-CSF. Our results also showed
that expression of Irf8 mRNA and protein in BMMs
obtained from Irf8fl/fl;Lyz2cre/?mice and cultured with
M-CSF was reduced. These findings predicted that
Lyz2/Lyz2-cre expression is induced when BMCs
differentiate into BMMs in cultures with M-CSF. In
osteoclast differentiation cultures, Lyz2 was gradually
increased by M-CSF during the first 3 days of culture,
then rapidly decreased by the addition of RANKLwith
M-CSF during the next 3 days. Furthermore, BMCs
differentiated into osteoclasts while maintaining a low
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level of Lyz2 expression when cultured simultaneously
with both M-CSF and RANKL from the initiation of
culture. These findings suggest that Lyz2-cre expres-
sion is induced along with differentiation to BMMs by
BMCs obtained from Irf8fl/fl;Lyz2cre/? mice and cul-
tured with M-CSF. In addition, Irf8 was down-
regulated by activation of the cre/loxP recombination
system in BMMs and osteoclastogenesis was acceler-
ated. Based on our results, we propose the existence
in vivo of a new lineage of osteoclast precursors
among BMCs, which differentiate into osteoclasts
without up-regulation of Lyz2 expression.
Keywords BMMs  Irf8  Lysozyme M  Lyz2 
Osteoclasts
Introduction
The strength and health of bone tissues are regulated
by a tight balance of bone resorption by osteoclasts
and bone formation by osteoblasts. When that balance
is destructed along with enhanced osteoclast and/or
failed osteoblast function, bone develops osteopenia
or osteoporosis, which is associated with a high risk of
fracture. Osteoclasts are differentiated from osteoclast
precursors with a monocyte/macrophage lineage fol-
lowing stimulation with macrophage colony-stimulat-
ing factor (M-CSF) and receptor activator of nuclear
factor-jB ligand (RANKL), which are secreted from
osteoblasts and osteocytes (Kobayashi et al. 2009;
Nakashima et al. 2012). Osteoclast differentiation and
activation are strictly controlled by various transcrip-
tion factors, including AP-1 (Fos/Jun) and nuclear
factor of activated T cells c1 (NFATc1), which are
activated by RANKL signaling. Differentiated osteo-
clasts express several specific markers, including
tartrate-resistant acid phosphatase (TRAP) and
cathepsin K, a cysteine protease.
We previously reported that interferon regulatory
factor 8 (IRF8), a transcription factor otherwise known
as interferon consensus sequence binding protein
(ICSBP), negatively regulates osteoclast differentia-
tion (Zhao et al. 2009). Irf8 is expressed in osteoclast
precursors and inhibits Nfatc1 function, and is down-
regulated by stimulation with RANKL, which leads to
Nfatc1 auto-amplification and osteoclast differentia-
tion. Furthermore, Irf8 global knockout (Irf8-/-) mice
show reduced bone volume as a result of increased
numbers of osteoclasts.
The population and properties of hematopoietic
cells in Irf8-/-mouse bone marrow and spleen tissues
are dramatically changed, along with development of
chronic myelogenous leukemia and splenomegaly
(Holtschke et al. 1996; Tamura et al. 2015; Tamura
and Ozato 2002), thus it is difficult to clearly analyze
the functions of Irf8 in monocytes/macrophages in the
osteoclast precursor stage. In the present study, to
investigate the detailed functions of Irf8 in mono-
cytes/macrophages during osoteoclastogenesis, we
established myeloid cell-specific Irf8 conditional
knockout (Irf8fl/fl;Lyz2cre/?) mice by crossing Irf8-flox
with Lyz2-cre mice, and analyzed bone phenotype and
osteoclast differentiation.
Materials and methods
Generation of mice
All animal experiments were conducted in accordance
with the guidelines of Showa University. The Irf8
knockout (Irf8-/-) mice (C57BL/6) used in this study
have been described (Holtschke et al. 1996). Myeloid
cell-specific Irf8 conditional knockout (Irf8fl/fl;Lyz2cre/?)
mice (C57BL/6) were generated by mating Irf8-flox
with Lyz2-cre knock-in mice (Clausen et al. 1999; Feng
et al. 2011). The primers used for genotyping are shown
in Table S1.
X-ray micro-tomography
Following euthanasia, tibiae were dissected and
subjected to three-dimensional micro-computed
tomography (lCT) with a ScanXmate-L090H (Com-
scan Tecno, Yokohama, Japan). Three-dimensional
microstructural image data thus obtained were recon-
structed using TRI/3D-BON software (Ratoc System
Engineering, Tokyo, Japan).
Cell cultures
Mouse bone marrow cells (BMCs) were collected
from the femora and tibiae of 6- to 8-week-old male
mice. Bone marrow-derived macrophages (BMMs)
were formed from BMCs cultured in a-MEM supple-
mented with 10 % fetal bovine serum and M-CSF
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(50 ng/mL) for 3–4 days at 37 C in a CO2 incubator
(5 % CO2, 95 % air). Osteoclasts were formed from
BMM (or BMC in Fig. 3c, d) cultures withM-CSF and
various concentrations of RANKL after 3–4 days.
Human M-CSF (Leucoprol) and RANKL was pur-
chased from Kyowa Hakko Kogyo (Tokyo, Japan) and
R&D Systems (Minneapolis, MN, USA), respectively.
Detection of osteoclasts and measurement
of TRAP activity
After culturing, cells were fixed with formalin and
stained for tartrate-resistant acid phosphatase (TRAP;
osteoclast marker) using a conventional method with
naphthol AS-MX phosphate (Sigma-Aldrich, St.
Louis, MO, USA) and fast red violet LB salt
(Sigma-Aldrich) dissolved in 0.1 M acetic buffer
(pH 5.0) containing 1 % tartrate acid (Suda et al.
1997). To evaluate the generation of osteoclasts, we
used a TRAP activity assay, as previously described
(Mochizuki et al. 2006).
Western blot analysis
Cells were lysed in RIPA buffer and quantified using a
BCA Protein Assay Kit (Thermo Scientific, Waltham,
MA, USA). SDS-polyacrylamide gel electrophoresis
sample buffer was added to protein samples (30 lg),
followed by boiling for 5 min. Next, the samples were
loaded onto pre-cast gradient Mini-PROTEAN TGX
Gels (Bio-Rad Laboratories, Hercules, CA,USA), then
separated and transferred to PVDF Immobilon-P
membranes (Merck Millipore, Billerica, MA, USA)
using a Mini Trans-Blot Cell system (Bio-Rad Labo-
ratories). The membranes were blocked in 5 % BSA
Tris-buffered saline-Tween 20, incubated with pri-
mary antibodies according to the supplier’s instruc-
tions, and incubated with appropriate HRP-conjugated
secondary antibodies prior to signal detection with
SuperSignal West Substrate (Thermo Scientific) using
a VersaDoc Imaging System (Bio-Rad Laboratories).
The antibodies used in the present experiment were as
follows: anti-Irf8 antibody (Icsbp) #sc6058 (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-b-
actin antibody #A5060 (Sigma-Aldrich), anti-goat
IgG-HRP #sc2768 (Santa Cruz Biotechnology), and
anti-rabbit IgG-HRP #7074 (Cell Signaling Technol-
ogy, Danvers, MA, USA).
Quantitative real-time PCR
Total RNA was extracted with TRIzol reagent (Invit-
rogen, Carlsbad, CA, USA), then reverse-transcribed
using ReverTra Ace qPCRRTMaster Mix (TOYOBO,
Osaka, Japan). Quantitative real-time PCR (qPCR)was
performed using THUNDERBIRD SYBR qPCR Mix
(TOYOBO) and the StepOne Real-Time PCR System
(Applied Biosystems, Foster City, CA, USA). The
primer sequences were as follows: Actb, 50-AGATGA
CCCAGATCATGTTTGAGA-30 and 50-CACAGCCT
GGATGGCTACGT-30; Irf8, 50-GGTGGATGCTTCC
ATCTTCAA-30 and 50-GTGGCTGGTTCAGCTTTG
TCT-30; Ctsk, 50-CGACTATCGAAAGAAAGGATA
CGTT-30 and 50-AGCCCAACAGGAACCACACT-30;
and Lyz2, 50-AATGGCTGGCTACTATGGAGTCA-30
and 50-TGCTCTCGTGCTGAGCTAAACA-30. Expre-
ssions were normalized to that of Actb.
Statistical analysis
The results are expressed as the mean ± SD for each
experiment. Student’s two-tailed t test was used, with
p\ 0.05 considered to indicate significance.
Results
We initially evaluated the bone morphology of Irf8fl/fl;
Lyz2cre/?mice, for which tibiae from proximal sides of
8-week-old males were analyzed using lCT. As we
previously reported, trabecular bone in Irf8-/- mice
was found to be sparse (Fig. 1a) and bone volume per
tissue volume (BV/TV) of tibia trabecular bone in
those mice was reduced by approximately 50 % as
compared to that of wild-type mice (Fig. 1b). On the
other hand, as compared to the control group (Irf8fl/fl or
Irf8 fl/?;Lyz2cre/?), trabecular bone in the Irf8fl/fl;
Lyz2cre/? mice was not altered (Fig. 1a) and BV/TV
was not significantly changed (Fig. 1b). Furthermore,
there were no significant difference in regard to BV/
TV between the control group and wild-type mice. In
addition, the body weights of the Irf8fl/fl;Lyz2cre/?
mice during development were not different as
compared to the control mice, while splenomegaly
was observed in the Irf8-/- but not the Irf8fl/fl;Lyz2cre/?
mice (data not shown). These results suggest that
osteoclastogenesis in bone tissues of Irf8fl/fl;Lyz2cre/?
mice is not enhanced in vivo.
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Next, to investigate the potential of Irf8fl/fl;Lyz2cre/?
mouse BMMs to differentiate into osteoclasts in vitro,
we used a conventional osteoclast culture system, in
which BMCs were induced to differentiate into BMMs
by M-CSF, then the BMMs were differentiated into
osteoclasts by addition of M-CSF and RANKL
(Fig. 2a). We found that osteoclast formation by
BMMs from Irf8fl/fl;Lyz2cre/? mice was enhanced as
compared to the control group, while that by BMMs
from Irf8-/- mice was enhanced as compared to the
wild-type mice (Fig. 2b, upper panels). Furthermore,
TRAP activity in osteoclasts from the Irf8fl/fl;Lyz2cre/?
mice was significantly increased as compared to the
control, while alterations in the Irf8-/- and wild-type
mice were similar (Fig. 2b, lower graphs). Using this
culture system, we also evaluated mRNA and protein
expression levels of Irf8 using qPCR and western
blotting, respectively. Our results showed that Irf8
mRNA expression in BMCs was not significantly
different between the control and Irf8fl/fl;Lyz2cre/?
mice (Fig. 2c, day 0), while that in BMMs from Irf8fl/fl;
Lyz2cre/? mice induced by M-CSF was significantly
suppressed as compared to the control group (Fig. 2c,
days 1–4). In addition, the Irf8 protein expression level in
BMMs induced from BMCs of Irf8fl/fl;Lyz2cre/? mice
after 3 days of culture with M-CSF was decreased as
compared to the control mice (Fig. 2d). Together, these
findings suggest that the progression of differentiation of
Irf8fl/fl;Lyz2cre/? mouse BMMs to osteoclasts in vitro is
induced by suppression of Irf8 expression in BMMs
caused by the presence of M-CSF in the culture.
Our results predicted that Lyz2/Lyz2-cre expres-
sion is induced when BMCs differentiate into BMMs
in cultures with M-CSF, using a conventional osteo-
clast culture system, thus we investigated the fluctu-
ation of Lyz2 mRNA expression using qPCR. Those
results confirmed that the expression of Ctsk (encodes
Cathepsin K; osteoclast marker) was greatly
increased, while that of Irf8 was reduced by stimula-
tion with RANKL (Fig. 3a, days 4–6). Therefore, we
found that the expression of Lyz2 was gradually
increased by M-CSF (Fig. 3a, days 1–3) and rapidly
decreased by RANKL stimulation (Fig. 3a, days 4–6).
Next, to examine whether osteoclast precursors among
BMCs are able to differentiate into osteoclasts without
the increased expression of Lyz2 seen in M-CSF-
cultured BMMs, we compared BMC cultures between
those stimulated with only M-CSF and those simul-
taneously stimulated with both M-CSF and RANKL
from the initiation of culture (Fig. 3b). Those finding
showed that TRAP-positive osteoclasts were formed
from cultures of BMCs stimulated by both M-CSF and
RANKL (Fig. 3c), as well as dramatic time-dependent
up-regulation of Ctsk expression in BMCs cultured
under that condition (Fig. 3d). Also, BMCs stimulated
simultaneously with both M-CSF and RANKL main-
tained low expression levels of Irf8 and Lyz2 as
compared to those cultured with only M-CSF
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Fig. 1 Irf8fl/fl;Lyz2cre/? mice did not develop osteoporosis.
a Representative lCT images of vertical (upper panels) and
axial (lower panels) tibiae obtained from 8-week-old male mice
of the indicated genotypes. b lCT analysis of bone volume per
tissue volume (BV/TV) of tibia trabecular bone (wild-type,
n = 8; Irf8-/-, n = 6; control, n = 20; Irf8fl/fl;Lyz2cre/?,
n = 23). **p\ 0.01; n.s. not significant
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(Fig. 3d). These results indicate that osteoclast pre-
cursors among BMCs are able to differentiate into
osteoclasts without up-regulation of Lyz2 expression
when in the presence of both M-CSF and RANKL
from the initiation of culture.
Discussion
In contrast to Irf8-/- mice, the Irf8fl/fl;Lyz2cre/? mice
did not develop osteoporosis. However, BMMs from
the Irf8fl/fl;Lyz2cre/? mice with a low level of Irf8
expression induced by M-CSF from BMCs in vitro
aggressively differentiated into osteoclasts by
RANKL stimulation, similar to those from the
Irf8-/- mice. We also noted that Lyz2 expression
was up-regulated in cultures with M-CSF, namely,
Lyz2 expression in BMMs was higher than that in
BMCs. These results suggested that Lyz2-cre was
induced along with the differentiation of BMCs from
Irf8fl/fl;Lyz2cre/? mice to BMMs when exposed to
M-CSF. Thereafter, loxP-flanked Irf8 DNA was
deleted by activation of the cre/loxP recombination
system in BMMs from Irf8fl/fl;Lyz2cre/? mice and
osteoclastogenesis induced by RANKL was acceler-
ated (Fig. 4a).
On the other hand, this is the first study to show that
osteoclast precursors among BMCs differentiated into
osteoclasts while maintaining a low level of Lyz2
expression when simultaneously exposed to both
M-CSF and RANKL from the initiation of culture.
That finding raises the possibility of another osteoclast
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Fig. 2 Osteoclastogenesis
induced in vitro by M-CSF
and RANKL was enhanced
in cultures of BMMs
obtained from Irf8fl/fl;
Lyz2cre/? mice. a Schema of
conventional osteoclast
culture system.
b Representative TRAP
staining of osteoclasts
differentiated from BMMs
cultured with M-CSF and
RANKL (20 ng/mL) for the
indicated genotypes (upper
panels). Shown is TRAP
activity of osteoclasts
differentiated from BMMs
cultured with M-CSF and
the indicated doses of
RANKL (lower graphs).
c qPCR analysis of Irf8
mRNA expression in BMCs
from control and Irf8fl/fl;
Lyz2cre/? mice cultured with
M-CSF for 0–4 days.
d Western blot analysis of
Irf8 and b-actin in BMMs
differentiated from BMCs
after 3 days of culture with
M-CSF. *p\ 0.05,
**p\ 0.01; n.s. not
significant
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lineage that differentiates from osteoclast precursors
among BMCs and does not express Lyz2/Lyz2-cre,
which may be dominant in vivo as compared to
osteoclasts with BMM lineage (Fig. 4b). Irf8 mRNA
expression was not reduced in BMCs from Irf8fl/fl;
Lyz2cre/? mice and those mice did not demonstrate
osteoporosis. Thus, if most osteoclasts differentiate
from BMMs in vivo, then Irf8fl/fl;Lyz2cre/? mice
should develop osteoporosis caused by enhancement
of excessive bone resorption induced by osteoclasto-
genesis, the same as seen in Irf8-/- mice. However,
that does not occur in Irf8fl/fl;Lyz2cre/? mice. A
previous study showed that mice obtained by crossing
Nfatc1 conditional knockout mice with Lyz2-cre mice
had no alterations in bone density (Aliprantis et al.
2008). Nfatc1 is a master regulator of osteoclast
differentiation and activated by RANKL, and its
transcriptional activity and expression are inhibited by
Irf8 in osteoclast precursors (Zhao et al. 2009). In
other words, the main portion of osteoclasts in vivo is
the results of differentiation from osteoclast precursors
under regulations of Irf8 and Nfatc1, without Lyz2/
Lyz2-cre expression. However, Lyz2-cre mice have
been used in osteoclast differentiation studies, and
conditional knockout mice have been found to have
such bone phenotypes as osteoporosis (Albers et al.
2013; Martin-Millan et al. 2010) and osteopetrosis
(Kenner et al. 2004; Wang et al. 2008). Thus, the
process of osteoclast differentiation may be dependent
on a combination of between expression level and/or
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Fig. 3 Lyz2 is up-regulated by M-CSF and down-regulated by
RANKL in BMC and BMM cultures. a qPCR analysis of Ctsk,
Irf8, and Lyz2mRNA expressions in BMCs fromwild-typemice
cultured with M-CSF for days 0–3, then with M-CSF and
RANKL (100 ng/mL) for days 4–6. b Schema of direct
osteoclast culture system using BMCs. c Representative TRAP
staining of osteoclasts differentiated from BMCs cultured with
only M-CSF, or simultaneously with both M-CSF and RANKL
(100 ng/mL) from the initiation of culture. d qPCR analysis of
Ctsk, Irf8, and Lyz2 mRNA expressions in BMCs from wild-
type mice cultured with only M-CSF, or simultaneously with
both M-CSF and RANKL (100 ng/mL) for 4 days from the
initiation of culture (lower panel). *p\ 0.05, **p\ 0.01
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function of each regulator, and two types of osteoclast
precursors, those with and without Lyz2/Lyz2-cre
expression. Additional studies are needed to elucidate
the mechanisms involved.
Acknowledgments We express our gratitude toM. Benton for
his help with our work. We thank H. Morse III (National
Institute of Allergy and Infectious Diseases, Rockville, MD,
USA) for providing Irf8-flox mice. This study was supported in
part by Grants-in-Aid for Scientific Research (B) (MT:
26293398) and (C) (AM: 15K11052) from the Japan Society
for the Promotion of Science.
Compliance with ethical standards
Conflicts of interest The authors have no conflicts of interest
to declare in regard to this study.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unre-
stricted use, distribution, and reproduction in any medium,
provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Com-
mons license, and indicate if changes were made.
References
Albers J et al (2013) Canonical Wnt signaling inhibits osteo-
clastogenesis independent of osteoprotegerin. J Cell Biol
200:537–549. doi:10.1083/jcb.201207142
Aliprantis AO et al (2008) NFATc1 in mice represses osteo-
protegerin during osteoclastogenesis and dissociates sys-
temic osteopenia from inflammation in cherubism. J Clin
Invest 118:3775–3789. doi:10.1172/JCI35711
Clausen BE, Burkhardt C, Reith W, Renkawitz R, Forster I
(1999) Conditional gene targeting in macrophages and
granulocytes using LysMcre mice. Transgenic Res
8:265–277
Feng J, Wang H, Shin DM, Masiuk M, Qi CF, Morse HC 3rd
(2011) IFN regulatory factor 8 restricts the size of the
marginal zone and follicular B cell pools. J Immunol
186:1458–1466. doi:10.4049/jimmunol.1001950
M-CSF + RANKLM-CSF
BMCs BMMs Osteoclasts
A 
B 
Control
Irf8fl/fl; 
Lyz2cre/+ 
Irf8 Irf8
Irf8 Lyz2-cre
In vitro
In vivo M-CSF
Irf8fl/fl; 
Lyz2cre/+ 
Irf8
Lyz2-creBMCs
BMMs
M-CSF + RANKL
Osteoclasts
M-CSF + RANKL
Irf8
Irf8
Fig. 4 Schematic representation of osteoclastogenesis of Irf8fl/fl;
Lyz2cre/? mouse BMCs in vitro and in vivo. a Lyz2-cre was
induced along with differentiation of BMCs from Irf8fl/fl;Lyz2cre/?
mice into BMMs in cultures with M-CSF. Irf8 in the BMMs was
then deleted by activation of the cre/loxP recombination system
and osteoclastogenesis was accelerated. b Proposed novel in vivo
differentiation lineage, in which osteoclast precursors among
BMCs differentiate into osteoclasts by simultaneous exposure to
M-CSF and RANKL, and do not showLyz2/Lyz2-cre expression.
This differentiation lineage may be dominant in vivo and could
explain why Irf8fl/fl;Lyz2cre/? mice do not develop osteoporosis
Cytotechnology
123
Holtschke T et al (1996) Immunodeficiency and chronic myel-
ogenous leukemia-like syndrome in mice with a targeted
mutation of the ICSBP gene. Cell 87:307–317
Kenner L et al (2004) Mice lacking JunB are osteopenic due to
cell-autonomous osteoblast and osteoclast defects. J Cell
Biol 164:613–623. doi:10.1083/jcb.200308155
Kobayashi Y, Udagawa N, Takahashi N (2009) Action of
RANKL and OPG for osteoclastogenesis. Crit Rev
Eukaryot Gene Expr 19:61–72
Martin-Millan M et al (2010) The estrogen receptor-alpha in
osteoclasts mediates the protective effects of estrogens on
cancellous but not cortical bone. Mol Endocrinol
24:323–334. doi:10.1210/me.2009-0354
Mochizuki A et al (2006) Identification and characterization of
the precursors committed to osteoclasts induced by TNF-
related activation-induced cytokine/receptor activator of
NF-kappa B ligand. J Immunol 177:4360–4368
Nakashima T, Hayashi M, Takayanagi H (2012) New insights
into osteoclastogenic signaling mechanisms. Trends
Endocrinol Metab 23:582–590. doi:10.1016/j.tem.2012.
05.005
Suda T, Jimi E, Nakamura I, Takahashi N (1997) Role of 1
alpha,25-dihydroxyvitamin D3 in osteoclast differentiation
and function. Methods Enzymol 282:223–235
Tamura T, Ozato K (2002) ICSBP/IRF-8: its regulatory roles in
the development of myeloid cells. J Interf Cytokine Res
22:145–152. doi:10.1089/107999002753452755
Tamura T, Kurotaki D, Koizumi S (2015) Regulation of mye-
lopoiesis by the transcription factor IRF8. Int J Hematol
101:342–351. doi:10.1007/s12185-015-1761-9
Wang Y, Lebowitz D, Sun C, Thang H, Grynpas MD, Glogauer
M (2008) Identifying the relative contributions of Rac1 and
Rac2 to osteoclastogenesis. J Bone Miner Res 23:260–270.
doi:10.1359/jbmr.071013
Zhao B et al (2009) Interferon regulatory factor-8 regulates bone
metabolism by suppressing osteoclastogenesis. Nat Med
15:1066–1071. doi:10.1038/nm.2007
Cytotechnology
123
Suppl. Table 1. Saito, E. et al. 
Gene target Primer sequence Product size (bp) 
Irf8 knockout 5'-CATGGCACTGGTCCAGATGTCTTCC-3' 
259 (wild-type) 
547 (knockout)   5'-CTTCCAGGGGATACGGAACATGGTC-3' 
  5'-CGAAGGAGCAAAGCTGCTATTGGCC-3' 
Irf8-flox 5'-TTGGGGATTTCCAGGCTGTTCTA-3' 214 (wild-type) 
300 (flox) 5'-CACAGGGAGTCCCTCTTACAAT-3' 
Lyz2-cre 5'-CTTGGGCTGCCAGAATTTCTC-3' (common) 
300 (wild-type) 
750 (cre)   5'-TTACAGTCGGCCAGGCTGAC-3' (wild-type) 
  5'-CCCAGAAATGCCAGATTACG-3' (mutant) 
